Japan · Delayed Price · Currency is JPY Oncolys BioPharma Company Description
Oncolys BioPharma Inc. engages in the research, development, manufacturing, and sale of viral infectious disease treatment drugs in Japan, the United States, and Asia.
The company offers Telomelysin (OBP-301), an oncolytic adenovirus, which is in Phase II clinical trial for the treatment of esophageal, gastric, and head and neck cancers, as well as hepatocellular carcinoma; and OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor, which is in Phase IIb clinical trial for the treatment of HIV infection.
It also provides products in the pre-clinical trial stage, including OBP-2011, a compound for the treatment of SARS-CoV-2 virus infection; OBP-702, a telomerase-specific oncolytic adenovirus for the treatment of solid tumors; and OBP-801, a histone deacetylase inhibitor for the treatment of lung cancer, lymphoma, kidney cancer, and glaucoma, as well as TelomeScan (OBP-401 and OBP-1101), an adenovirus, which is in clinical study for detecting living circulating tumor cells.
In addition, it is involved in the diagnostic, clinical testing, and inspection businesses. The company was incorporated in 2004 and is headquartered in Minato, Japan.
| Country | Japan |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Yasuo Urata |
Contact Details
Address: Toranomon Towers Office Minato, 105-0001 Japan | |
| Phone | 81 3 5472 1578 |
| Website | oncolys.com |
Stock Details
| Ticker Symbol | 4588 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3202170001 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yasuo Urata | Chief Executive Officer |